HealthWatch: Targeting ALK Positive Lung Cancer: Bruce’s Story

Health Watch
Healthwatch__Pediatric_Sports_Medicine_0_20180718224323

NEW YORK CITY, N.Y. (Ivanhoe Newswire) — Many lung cancer patients who have never smoked and don’t work around toxic chemicals or carcinogens have been found instead to have a defective gene that drives their cancer. Now, an FDA- approved therapy is targeting what doctors call ALK positive cancer, helping push patients toward remission.
Most mornings, you’ll find Bruce Dunbar powering through a workout with the Westchester, New York, Master’s swim club. Bruce was a high school All-American and captain of the Princeton swim team. Now at 52, swimming is good for his body, and his mind.
Dunbar told Ivanhoe, “The truth is, it’s a chance to think about what the day has in store. What life has in store.”
Two years ago, Dunbar’s life was flipped upside down. What doctors first thought was asthma or pneumonia was finally diagnosed as stage four lung cancer. It had spread to his spine and his brain.
“As it turns out, I had 26 lesions in my brain,” Dunbar said.
Dunbar never smoked. His doctors determined he had a gene mutation driving the cancer.
“Bruce wound up having something called an ALK rearrangement, which is a mutation, different parts of the chromosome fused together, and fortunately, that has amazing drugs now,” said Brendon Stiles, MD, Thoracic Surgeon at Weill Cornell Medicine & NY-Presbyterian.
In fact, just one month before Dunbar was diagnosed, the FDA approved Alecensa and his oncologist prescribed it. Four pills twice a day.
Now more than 20 months later, Dunbar has just three tumors in his brain. The tumor in his lung is only one-tenth of what it used to be.
“In November of 2017 when I was diagnosed I wasn’t sure I was going to live, let alone get back in a pool again,” Dunbar said.
Back swimming and competing as long as he can.
Doctors say eventually the drug will stop working and the cancer will regrow. The hope is that the targeted therapy works long enough for researchers to refine the next generation of the drug, or add another treatment, like immunotherapy to keep Dunbar going. Bruce says he has had some minimal side effects from the drug including fatigue, weight gain, and a suppressed heart rate.

Contributors to this news report include: Cyndy McGrath, Field Producer; Jamison Koczan, Editor; and Kirk Manson, Videographer.
Free weekly e-mail on Medical Breakthroughs from Ivanhoe. To sign up: http://www.ivanhoe.com/ftk

MEDICAL BREAKTHROUGHS
RESEARCH SUMMARY

TOPIC: TARGETING ALK POSITIVE LUNG CANCER: BRUCE’S STORY
REPORT: MB #4612

BACKGROUND: ALK positive lung cancer is a genetic alteration of a patient’s lung cell DNA. It is more likely to happen in younger patients, 55 and younger, who have never smoked. The ALK mutation causes the cells to grow abnormally and behave as cancer cells. Once the cells begin to grow in the lung they can spread into other parts of the body. If the lung cancer positive for the ALK mutation is found in an earlier stage, it can be treated quickly with surgery.
(Source: https://lcfamerica.org/lung-cancer-info/types-lung-cancer/alk-positive-lung-cancer/)

TREATMENT: Many patients that are diagnosed with lung cancer with ALK can be treated using targeted therapy. If the cancer is not found in an earlier stage allowing for a patient to just get surgery to remove the cancer, then they will most likely be treated with ALK inhibitors. ALK inhibitors target the ALK mutation and stop the cancer from growing and spreading. These inhibitors have been great for patients because they are effective for years. The problem with some of the older inhibitors is the cancer cells eventually develop a resistance to the drugs and can start growing again. Some newer inhibitors overcome the cancer cells resistance and re-establish the effectiveness of the drugs. Other treatments like radiation therapy, chemotherapy, and immunotherapy are also options for patients.
(Source: https://lcfamerica.org/lung-cancer-info/types-lung-cancer/alk-positive-lung-cancer/)

ALECTINIB: Brendon Stiles, MD, Thoracic Surgeon, Weill Cornell Medicine & NY-Presbyterian talks about a new drug, called alectinib, to help patients with ALK positive lung cancer, and how it helped one of his patients. “Alectinib had had some studies in later stage, in the second line setting really just the month that Bruce got diagnosed, the drug got approved as first line therapy for ALK rearranged lung cancer. The important part about that was that the study had shown the drug not only worked better everywhere in the body, but it works significantly better in the brain,” said Stiles. In the case of a patient like Bruce, who had stage four lung cancer, it has completely saved his life. “Almost all of his spots have almost completely shrunk. He still has some that are visible. But we don’t think any are active,” says Stiles. Alectinib is also much easier for patients because it is an oral therapy as compared to infusion or chemotherapy.
(Source: Brendon Stiles, MD)

FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT:

Anna Sokol, PR
646-962-9472
ana2059@med.cornell.edu

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at mthomas@ivanhoe.com

Copyright 2021 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Don't Miss

More Don't Miss

Coronavirus News

More Coronavirus
HealthWatch Logo

Trending Stories

Your Local Election HQ

More Election

Local Sports

High School Sports Xtra: Bay Port's Westerman talks spring football

High School Sports Xtra: Local 5 Top 5 Plays, Team of the Week

High School Sports Xtra: State Boys Basketball Recap

Gamblers complete the sweep of Youngstown

Papermakers fall in Division One state title game against

Discipline and preparation carries Kimberly boys basketball into state championship game